Company Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases.
The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
| Country | United States |
| Founded | 1986 |
| IPO Date | Mar 3, 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 536 |
| CEO | Jon P. Stonehouse |
Contact Details
Address: 4505 Emperor Boulevard, Suite 200 Durham, North Carolina 27703 United States | |
| Phone | 919-859-1302 |
| Website | biocryst.com |
Stock Details
| Ticker Symbol | BCRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000882796 |
| CUSIP Number | 09058V103 |
| ISIN Number | US09058V1035 |
| Employer ID | 62-1413174 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jon P. Stonehouse | Chief Executive Officer, President and Executive Director |
| Anthony J. Doyle | Senior Vice President, Chief Financial Officer and Treasurer |
| Alane P. Barnes | Senior Vice President, Chief Legal Officer and Corporate Secretary |
| Dr. William P. Sheridan MBBS | Chief Development Officer |
| Dr. Yarlagadda S. Babu | Chief Discovery Officer |
| Dr. Helen M. Thackray FAAP, M.D. | Chief Research and Development Officer |
| Charles K. Gayer | Senior Vice President and Chief Commercial Officer |
| Michael L. Jones | Executive Director of Finance and Principal Accounting Officer |
| John D. Bluth | Chief Communications Officer |
| Stephanie Angelini | Chief People Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 24, 2024 | 144 | Filing |
| Jun 17, 2024 | 144 | Filing |
| Jun 14, 2024 | 144 | Filing |
| Jun 13, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 6, 2024 | 8-K | Current Report |
| Apr 25, 2024 | ARS | Filing |
| Apr 25, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 25, 2024 | DEF 14A | Other definitive proxy statements |
| Feb 27, 2024 | S-3ASR | Automatic shelf registration statement of securities of well-known seasoned issuers |